2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab)
Stefano Cascinu(Vita-Salute San Raffaele University), Irene Floriani(Mario Negri Institute for Pharmacological Research), Monica Giordano(Ospedale Sant'Anna), Vittorina Zagonel(Istituto Oncologico Veneto), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Francesco Ferraù(Université Paris-Sud), Sara Lonardi(Istituto Oncologico Veneto), Eliana Rulli(Mario Negri Institute for Pharmacological Research), Domenico Corsi(Ospedale San Carlo), Adriana Romiti(Sapienza University of Rome), Guglielmo Nasti, Roberto Labianca(Ospedale Papa Giovanni XXIII), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Vincenzo Rosario Iaffaioli, Gerardo Rosati(Ospedale San Carlo), Massimo Aglietta(Candiolo Cancer Institute), Rossana Berardi(Marche Polytechnic University)
Cited by 5
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k